Published

Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: eYLS (Yale Law School)
Date: 2025-12-02
Source: OpenAlex
DOI: Unavailable
PubMed: Unavailable

Authors

Spohn Kyle

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Clinical Trial Treatment-Resistant Depression Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17 Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.Nature medicine · 2026-08-06 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psychedelic Therapy for DepressionUnknown journal · 2026-08-11 Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01 Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06